CIK 0001069530 · Non-accelerated filer<br>Smaller reporting company
FILANA THERAPEUTICS, INC.
Sign in to watch- Ticker
- FLNA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 911911336
- Phone
- 512-501-2444
- Business address
- 6801 N CAPITAL OF TEXAS HIGHWAY, BUILDING 1; SUITE 300, AUSTIN, TX, 78731
- Former names
- CASSAVA SCIENCES INC, PAIN THERAPEUTICS INC
- Open-market buys, last 90 days
- $356,328
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$356,328. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2010-05-17 | SCHOENHARD GRANT Chief Scientific Officer | Option exercise | +3,609 | $5.25 | $19K | 53,296 |
| 2010-05-17 | SCHOENHARD GRANT Chief Scientific Officer | Sale | −5,109 | $5.75 | $29K | 5,611 |
| 2010-05-17 | SCHOENHARD GRANT Chief Scientific Officer | Option exercise · Common Stock | +1,500 | $4.40 | $7K | 682,000 |
| 2010-05-17 | SCHOENHARD GRANT Chief Scientific Officer | Option exercise · Common Stock | +3,609 | $5.25 | $19K | 678,391 |
| 2010-05-06 | BARBIER REMI CEO and Chairman of BOD | Sale | −6,576 | $5.61 | $37K | 6,171,447 |
| 2010-05-05 | BARBIER REMI CEO and Chairman of BOD | Sale | −20,100 | $5.76 | $116K | 6,178,023 |
| 2010-05-04 | FRIEDMANN NADAV Chief Operating Officer | Sale | −15,000 | $5.95 | $89K | 275,951 |
| 2010-05-04 | BARBIER REMI CEO and Chairman of BOD | Sale | −11,400 | $5.94 | $68K | 6,198,123 |
| 2010-05-03 | RODDY PETER S Chief Financial Officer | Other acquisition | +3,983 | $3.77 | $15K | 42,396 |
| 2010-05-03 | FRIEDMANN NADAV Chief Operating Officer | Other acquisition | +3,756 | $3.77 | $14K | 290,951 |
| 2010-05-03 | BARBIER REMI CEO and Chairman of BOD | Sale | −11,924 | $6.14 | $73K | 6,209,523 |
| 2010-05-01 | RODDY PETER S CFO | Purchase | +3,983 | $3.77 | $15K | 42,396 |
| 2010-04-16 | SCHOENHARD GRANT Chief Scientific Officer | Option exercise | +1,500 | $4.40 | $7K | 49,687 |
| 2010-04-16 | SCHOENHARD GRANT Chief Scientific Officer | Option exercise | +25,000 | $5.25 | $131K | 74,687 |
| 2010-04-16 | SCHOENHARD GRANT Chief Scientific Officer | Sale | −26,500 | $6.29 | $167K | 48,187 |
| 2010-04-16 | SCHOENHARD GRANT Chief Scientific Officer | Option exercise · Common Stock | −1,500 | $4.40 | $7K | 708,500 |
| 2010-04-16 | SCHOENHARD GRANT Chief Scientific Officer | Option exercise · Common Stock | −25,000 | $5.25 | $131K | 683,500 |
| 2010-04-07 | BARBIER REMI CEO and Chairman of Board | Sale | −5,800 | $6.23 | $36K | 6,221,447 |
| 2010-04-06 | BARBIER REMI CEO & Chairman of the Board | Sale | −22,200 | $6.29 | $140K | 6,227,247 |
| 2010-04-05 | BARBIER REMI CEO & Chairman of the Board | Sale | −10,000 | $6.16 | $62K | 6,249,447 |
Page 24 of 25 · 498 trades